Table 2.
Occurrence of most common imbalances in different epithelial neoplasias by CGH
| Regional imbalance | Most frequent* | Above background | Putative targets** |
|
enh(1q) occuring in most carcinoma types |
Breast, ovary, HCC, cervix, NPC, MEL, endometrial, vulva | Gastric, CRC, HCC, HNSCC, NSCLC, ES, RCC, bladder, PAC, SCLC, SQS | ABL2, ETV3 |
| dim(3p) | HNSCC, NSCLC, cervix, ES, RCC, NE, MEL (whole chr. 3), SCLC, vulva, SQS | Gastric, PAC | FHIT, MLH1 |
|
enh(3q) maxima at 3q26q27 (except 3q25 in NPC) |
Ovary, HNSCC, NSCLC, cervix, ES, NPC, SCLC, endometrial, vulva, SQS | Gastric, RCC, PAC | BCL6, PIK3CA |
|
dim(4q) frequently whole chromosome |
Ovary, HCC, NSCLC, cervix, ES, bladder, cholangio, SCLC | Gastric, CRC, HNSCC, RCC, PAC, | PRDM5 |
| enh(5p) | Thyroid, NSCLC, cervix, | Gastric, ovary, CRC, HCC, HNSCC, ES, bladder, NE, PAC, cholangio, vulva | CDH6, TERT |
| dim(5q) | Ovary, NSCLC, | Prostate, gastric, HNSCC, ES, bladder, cholangio, | APC, MCC |
| enh(6p) | HCC, MEL | Ovary, NSCLC, cervix, ES, bladder, cholangio, SCLC, vulva | E2F3, ID4 |
|
dim(6q) maxima at 6q16q21 or 6q24q27 |
Prostate, RCC, MEL | Ovary, HCC, NSCLC, cervix, bladder, NE, PAC, cholangio, SCLC | CCNC |
|
enh(7) frequently whole 7, mostly max. on 7q |
Prostate, thyroid, ES, RCC | Gastric, ovary, CRC, HCC, HNSCC, bladder, MEL, PAC (7p>7q), cholangio (7p>7q) | 7p: EGFR 7q: ABCB1, MET |
| dim(8p) | Breast, prostate, CRC, HCC | Ovary, HNSCC, NSCLC, ES, RCC, bladder, PAC, SCLC, vulva | DLC1, MSR1, N33 |
|
enh(8q) ubiquitously high (exception NE and thyroid) |
Breast, prostate, ovary, CRC, HCC, HNSCC, NSCLC, ES, RCC, bladder, MEL, PAC, cholangio, endometrial, vulva | Cervix, NPC, SCLC, SQS | MYC |
|
dim(9p) 9p or whole 9 |
HNSCC, bladder, PAC, SQS | Gastric, NSCLC, ES, RCC, NPC, MEL, SCLC | ARF, CDKN2A |
|
enh(11q13) frequently distinct (high-level) gain |
HNSCC | Breast, gastric, ovary, NSCLC, ES, NPC, bladder, MEL, PAC, cholangio | CCND1, FGF3 |
| dim(11q23qter) | NPC, NE, vulva | Breast, HNSCC, cervix, ES, MEL, SCLC | ATM (11q22), (LOH11CR2 A, TSG11) |
|
enh(12p) frequently whole 12; slight max. on 12p |
NPC | Ovary, CRC, HNSCC, NSCLC, ES, RCC, PAC, vulva | 12p: CDK2, CDK4, GLI, KRAS 12q: MDM2 |
|
dim(13q) mostly 13q14q21 |
Prostate, HCC, thyroid, bladder, NE, PAC, SCLC, endometrial | Breast, gastric, ovary, HNSCC, NSCLC, cervix, ES, RCC, NPC (max. at 13q31), MEL, CRC, vulva | BRCA2, RB1, STARD13 |
| dim(16q) | Breast, NPC | Prostate, gastric, HCC, SCLC | CDH1, ATBF1 |
| dim(17p) | Breast, gastric, CRC, cholangio, SCLC | Ovary, HCC, NSCLC, cervix, ES, RCC, NPC, bladder, PAC, SQS | TP53 |
| enh(17q) | Breast, gastric, bladder, NE, PAC, cholangio, SCLC, SQS | HCC, HNSCC, NSCLC, cervix, ES, renal, NPC | ERBB2 |
| dim(18q) | Gastric, ovary, CRC, HNSCC, PAC, SQS | HCC, NSCLC, cervix, renal, bladder, cholangio | DCC, SMAD4 |
| enh(19q) | NE, SCLC | Breast, CRC, PAC, vulva | AKT2, BAX |
| enh(20q) | Gastric, CRC, thyroid, bladder, NE, PAC, cholangio | Breast, HCC, cervix, ES, renal, MEL, SCLC, vulva | STK15/AuroraA |
Please refer to table 1 for abbreviations. * "most frequent" lists entities in which the aberration belongs to the 3 most frequent imbalances of the specified quality (enh = gain, dim = loss; bold if most frequent change in entity). Entities are sorted according to the total number of included cases. Chromosomal regions 1p, 21, 22, X and Y were omitted due to differences in reporting (e.g. exclusion of regions prone to errors in chromosomal CGH analysis). ** Listed are some examples of genes with oncogene (for gain regions) or tumor suppressor (for loss regions) function. However, a large number of possible target genes as well as structural features may exist for each region.